693 related articles for article (PubMed ID: 34987749)
41. Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis.
Katel A; Aryal M; Neupane A; Gosain R; Pathak R; Bhandari Y; Kouides P
Cureus; 2021 Apr; 13(4):e14572. PubMed ID: 34026385
[TBL] [Abstract][Full Text] [Related]
42. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Martinelli I; Lensing AW; Middeldorp S; Levi M; Beyer-Westendorf J; van Bellen B; Bounameaux H; Brighton TA; Cohen AT; Trajanovic M; Gebel M; Lam P; Wells PS; Prins MH
Blood; 2016 Mar; 127(11):1417-25. PubMed ID: 26696010
[TBL] [Abstract][Full Text] [Related]
43. Thirteen-year trend in the persistence with vitamin K antagonists for venous thromboembolism in the UK: a cohort study.
Martinez C; Katholing A; Folkerts K; Rietbrock S
Curr Med Res Opin; 2018 Nov; 34(11):1985-1990. PubMed ID: 29798688
[TBL] [Abstract][Full Text] [Related]
44. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
Khan F; Rahman A; Carrier M; Kearon C; Weitz JI; Schulman S; Couturaud F; Eichinger S; Kyrle PA; Becattini C; Agnelli G; Brighton TA; Lensing AWA; Prins MH; Sabri E; Hutton B; Pinede L; Cushman M; Palareti G; Wells GA; Prandoni P; Büller HR; Rodger MA;
BMJ; 2019 Jul; 366():l4363. PubMed ID: 31340984
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study.
Lu K; Liao QQ; Zhu KW; Yao Y; Cui XJ; Chen P; Bi Y; Zhong M; Zhang H; Tang JC; Yu Q; Yue JK; He H; Zhu ZF; Cai ZZ; Yang Z; Zhang W; Dong YT; Wei QM; He X
Adv Ther; 2024 Jan; 41(1):391-412. PubMed ID: 37987918
[TBL] [Abstract][Full Text] [Related]
46. Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis.
Lurkin A; Derex L; Fambrini A; Bertoletti L; Epinat M; Mismetti P; Dargaud Y
Cerebrovasc Dis; 2019; 48(1-2):32-37. PubMed ID: 31480062
[TBL] [Abstract][Full Text] [Related]
47. Direct Oral Anticoagulants in Patients With Active Cancer: A Systematic Review and Meta-Analysis.
Sabatino J; De Rosa S; Polimeni A; Sorrentino S; Indolfi C
JACC CardioOncol; 2020 Sep; 2(3):428-440. PubMed ID: 34396250
[TBL] [Abstract][Full Text] [Related]
48. Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis.
Serrao A; Merli M; Lucani B; Aprile F; Fiori L; Gioia S; Breccia M; Riggio O; Chistolini A
Eur J Clin Invest; 2021 Jan; 51(1):e13356. PubMed ID: 33180323
[TBL] [Abstract][Full Text] [Related]
49. Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs.
Poli D; Antonucci E; Vignini E; Martinese L; Testa S; Simioni P; Pengo V; Pignatelli P; Falanga A; Masciocco L; Barcellona D; Ciampa A; Chiarugi P; Paparo C; Ageno W; Palareti G;
Eur J Intern Med; 2020 Oct; 80():73-77. PubMed ID: 32522446
[TBL] [Abstract][Full Text] [Related]
50. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
van Es N; Coppens M; Schulman S; Middeldorp S; Büller HR
Blood; 2014 Sep; 124(12):1968-75. PubMed ID: 24963045
[TBL] [Abstract][Full Text] [Related]
51. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
52. Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
Huisman MV; Ferreira M; Feuring M; Fraessdorf M; Klok FA
J Thromb Haemost; 2018 Sep; 16(9):1775-1778. PubMed ID: 29974611
[TBL] [Abstract][Full Text] [Related]
53. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis.
Chaudhary R; Pagali S; Garg J; Murad MH; Wysokinski WE; McBane RD
J Am Geriatr Soc; 2020 Sep; 68(9):2021-2026. PubMed ID: 32441334
[TBL] [Abstract][Full Text] [Related]
54. Outcome of Elderly Patients with Venous Thromboembolism Treated with Direct Oral Anticoagulants-A Retrospective Cohort Study.
Ayalon-Dangur I; Vega Y; Israel MR; Grossman A; Spectre G; Shochat T; Leibovici L; Gafter-Gvili A
J Clin Med; 2021 Dec; 10(23):. PubMed ID: 34884375
[TBL] [Abstract][Full Text] [Related]
55. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis.
La Mura V; Braham S; Tosetti G; Branchi F; Bitto N; Moia M; Fracanzani AL; Colombo M; Tripodi A; Primignani M
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1146-1152.e4. PubMed ID: 29066371
[TBL] [Abstract][Full Text] [Related]
56. DOACs use in extreme body-weighted patients: results from the prospective START-register.
Guarascio M; Bertù L; Donadini MP; Antonucci E; Palareti G; Ageno W
Intern Emerg Med; 2023 Sep; 18(6):1681-1687. PubMed ID: 37301770
[TBL] [Abstract][Full Text] [Related]
57. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
58. Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: A prospective cohort study.
Vedovati MC; Mancuso A; Pierpaoli L; Paliani U; Conti S; Ascani A; Galeotti G; Di Filippo F; Caponi C; Agnelli G; Becattini C
Int J Cardiol; 2020 Feb; 301():167-172. PubMed ID: 31761402
[TBL] [Abstract][Full Text] [Related]
59. Safety and effectiveness of direct oral anticoagulants following ultrasound-assisted catheter directed thrombolysis for venous thromboembolism.
Kelley D; Wright L; Ohman K; Ferreira J
J Thromb Thrombolysis; 2018 Jul; 46(1):58-61. PubMed ID: 29797208
[TBL] [Abstract][Full Text] [Related]
60. Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms.
Huenerbein K; Sadjadian P; Becker T; Kolatzki V; Deventer E; Engelhardt C; Griesshammer M; Wille K
Ann Hematol; 2021 Aug; 100(8):2015-2022. PubMed ID: 33216197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
